GlassScriptPhysician profile
Corinne Spero
NPI 1184171563
$9,970.02
in general payments reported to CMS, 2019-2025
27 companies · $2,939 in 2025
The $2,939 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $615 · 2022: $1,447 · 2023: $2,454 · 2024: $2,515 · 2025: $2,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,808 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,807.94 |
| Education | $100.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,494.06 | 2021-2025 | |
| Janssen Biotech, INC. | $1,721.91 | 2021-2025 | Tremfya, Stelara, Remicade |
| Amgen INC. | $1,359.21 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $553.21 | 2022-2025 | |
| Ucb, INC. | $445.88 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $431.44 | 2021-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $416.26 | 2021-2025 | Benlysta, Nucala |
| Sobi, INC | $298.48 | 2022-2025 | |
| Horizon Therapeutics Plc | $283.63 | 2021-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $282.17 | 2021-2024 | Orencia |
| Alexion Pharmaceuticals, INC. | $276.05 | 2021-2025 | Strensiq |
| Janssen Scientific Affairs, LLC | $273.91 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $262.36 | 2022-2025 | Saphnelo |
| Genzyme Corporation | $123.39 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $110.09 | 2022-2024 | Lupkynis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.64 | 2023-2024 | Cyltezo |
| Radius Health, INC. | $101.35 | 2022-2024 | Tymlos |
| Genentech USA, INC. | $82.07 | 2024-2025 | Actemra |
| Ani Pharmaceuticals, INC. | $78.83 | 2024-2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $66.28 | 2024 | Arcalyst |
| Sandoz INC. | $44.54 | 2023 | Hyrimoz |
| Pfizer INC. | $42.98 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $28.35 | 2023 | Arcalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $25.92 | 2025 | Cuvitru |
| Ultragenyx Pharmaceutical INC. | $21.72 | 2023 | |
| Kyowa Kirin, INC. | $20.31 | 2023 | Crysvita |
| Alfasigma USA, INC. | $18.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corinne Spero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.